Search clinical trials for: sargramostim GZ402664

Total 507 results

Sanofi

Withdrawn

Open Label Study of Sargramostim Among Patients Receiving Myelosuppressive Induction Chemotherapy for Acute Myelogenous Leukemia

Acute Myeloid Leukemia NOS
Sanofi
National Institute on Aging (NIA)

Withdrawn

Safety Study of Sargramostim in Treating Patients With Mild Cognitive Impairment Due to Alzheimer's Disease

Dementia Alzheimer's Type

United States
Genzyme, a Sanofi Company

Completed

Safety and Efficacy Evaluation of Repeat neoGAA Dosing in Late Onset Pompe Disease Patients.

Pompe Disease | Glycogen Storage Disease Type II (GSD II) | Acid Maltase Deficiency

United States, Belgium, Denmark, France, Germany, Netherlands, United Kingdom
Sanofi

Approved for marketing

Compassionate Use Program for Olipudase Alfa Enzyme Replacement Therapy for Patients With Chronic Acid Sphingomyelinase Deficiency (ASMD)

Sphingomyelin Lipidosis
Sanofi

Recruiting

Avalglucosidase Alfa Pregnancy Study

Pregnancy | Pompe Disease

United States
Sanofi

Recruiting

Clinical Study for Treatment-naïve IOPD Babies to Evaluate Efficacy and Safety of ERT With Avalglucosidase Alfa (Baby-COMET)

Glycogen Storage Disease Type II

Belgium, United States, China, Germany, Italy, Netherlands, Spain, Taiwan, United Kingdom
Genzyme, a Sanofi Company

Active, not recruiting

Avalglucosidase Alfa French Post-trial Access for Participants With Pompe Disease (PTA Avalglucosidase)

Glycogen Storage Disease Type II

France
Genzyme, a Sanofi Company

Completed

Tolerability and Safety Study of Recombinant Human Acid Sphingomyelinase in Acid Sphingomyelinase Deficiency Patients

Human Acid Sphingomyelinase Deficiency

United Kingdom, United States
Genzyme, a Sanofi Company

Completed

Avalglucosidase Alfa Extension Study (NEO-EXT)

Glycogen Storage Disease Type II Pompe Disease

United States, Belgium, Denmark, France, Germany, Netherlands, United Kingdom
Genzyme, a Sanofi Company

Terminated

A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients (STAGED-PKD)

Polycystic Kidney, Autosomal Dominant

Belgium, Germany, Czechia, United States, Italy, Poland, Argentina, Australia, Austria, Canada, China, Denmark, France, Israel, Japan, Korea, Republic of, Netherlands, Portugal, Romania, Spain, Taiwan, Turkey, United Kingdom
Genzyme, a Sanofi Company

Completed

Safety, Tolerability, PK, and Efficacy Evaluation of Repeat Ascending Doses of Olipudase Alfa in Pediatric Patients <18 Years of Age With Acid Sphingomyelinase Deficiency (ASCEND-Peds)

Sphingomyelin Lipidosis

Brazil, France, Italy, United States, Germany, United Kingdom
Sanofi

Terminated

Long-term Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) With Venglustat (STAGED-PKD-EXT)

Congenital Cystic Kidney Disease

Germany, Spain, United States, Australia, Belgium, Japan, Korea, Republic of, Netherlands
Vestre Viken Hospital Trust
Oslo University Hospital; University Hospital of North Norway; Helse Stavanger... and other collaborators

Recruiting

Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer (LUNGVAC)

Oncology | NSCLC Stage IV | NSCLC, Stage III

Norway
Genzyme, a Sanofi Company

Completed

A Long-Term Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency

Sphingomyelin Lipidosis

United States, Belgium, Brazil, France, Germany, Italy, United Kingdom
Genzyme, a Sanofi Company

Completed

Efficacy, Safety, Pharmacodynamic, and Pharmacokinetics Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency (ASCEND)

Sphingomyelin Lipidosis

United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Chile, France, Germany, Italy, Japan, Netherlands, Portugal, Spain, Tunisia, Turkey, United Kingdom
Genzyme, a Sanofi Company

Completed

Study to Compare the Efficacy and Safety of Enzyme Replacement Therapies Avalglucosidase Alfa and Alglucosidase Alfa Administered Every Other Week in Patients With Late-onset Pompe Disease Who Have Not Been Previously Treated for Pompe Disease (COMET)

Glycogen Storage Disease Type II;Pompe's Disease

Czechia, Taiwan, Belgium, Germany, Korea, Republic of, United States, Argentina, Australia, Austria, Brazil, Canada, Denmark, France, Hungary, Italy, Japan, Mexico, Netherlands, Poland, Portugal, Russian Federation, Spain, Switzerland, Turk... and more
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

GM-CSF in Treating Patients With Relapsed Prostate Cancer

Prostate Cancer

United States
Sanofi

Completed

A Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis

Progressive Multiple Sclerosis

Germany
University of Colorado, Denver
The Dana Foundation

Completed

Study of the Safety & Efficacy of Leukine® in the Treatment of Alzheimer's Disease

Alzheimer's Disease

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung

Metastatic Cancer | Melanoma (Skin)

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Sargramostim in Treating Patients With Kidney Cancer That Has Spread to the Lung

Kidney Cancer | Metastatic Cancer

United States, Canada
Milton S. Hershey Medical Center

Withdrawn

Inhaled GM-CSF for Respiratory Virus-Associated Severe Pneumonia (iGRASP)

Pneumonia | Acute Respiratory Distress Syndrome | Respiratory Virus Infection
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

Sargramostim in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission Following Initial Treatment

Leukemia

United States
Genzyme, a Sanofi Company

Completed

A First-in-human, Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis

Progressive Multiple Sclerosis

Germany
Roswell Park Cancer Institute

Completed

Sargramostim in Reducing Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplantation for Hematologic Cancer or Aplastic Anemia

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Graft Versus Host Disease | Myelodysplastic/Myeloproliferative Neoplasms

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung

Metastatic Cancer | Melanoma (Skin)

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Sargramostim After Bone Marrow Transplantation in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Diseases

United States
Genzyme, a Sanofi Company

Terminated

Open-label Trial of Leukine in Active Crohn's Disease

Crohn Disease

Switzerland, United States, New Zealand, Canada, Australia, Brazil, United Kingdom, Ukraine, Russian Federation, Argentina
Mayo Clinic
National Cancer Institute (NCI)

Completed

Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors

Glioma | Recurrent Childhood Medulloblastoma | Childhood Atypical Teratoid/Rhabdoid Tumor | Diffuse Intrinsic Pontine Glioma | Refractory Brain Neoplasm | Recurrent Childhood Anaplastic Oligodendroglioma | Recurrent Childhood Glioblastoma | Recurrent Primitive Neuroectodermal Tumor | Childhood Astrocytoma and other conditions

United States
University of Nebraska

Active, not recruiting

Biomarker Assessments of Leukine During Treatment of Parkinson's Disease

Parkinson Disease

United States
Children's Hospital Medical Center, Cincinnati
Genzyme, a Sanofi Company; Virginia Commonwealth University

Completed

Inhaled Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in Hereditary Pulmonary Alveolar Proteinosis (PAP) (FAMPAP)

Hereditary Pulmonary Alveolar Proteinosis

United States
Hospices Civils de Lyon

Completed

GM-CSF to Decrease ICU Acquired Infections (GRID)

Septic Shock | Severe Sepsis

France
Massachusetts General Hospital
Bayer; Dana-Farber Cancer Institute

Completed

GM-CSF, Sargramostim in Women With Recurrent Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer
Genzyme, a Sanofi Company

Terminated

Efficacy Study of Sargramostim in the Retreatment of Patients Who Have Crohn's Disease Who Have Previously Responded to Treatment With Sargramostim

Crohn Disease

United States
Genzyme, a Sanofi Company

Terminated

Safety and Efficacy Study in the Treatment of Pediatric Crohn's Disease

Crohn Disease

United States
University of Wisconsin, Madison
National Cancer Institute (NCI)

Completed

Vaccine Therapy With gp100 and/or Sargramostim in Treating Patients With Malignant Melanoma

Melanoma (Skin)

United States
Sirius Medicine

Completed

Radiation Therapy and Sargramostim in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...
National Cancer Institute (NCI)

Unknown

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
Genzyme, a Sanofi Company

Terminated

Efficacy (Induction of Response/Remission) and Safety Study in Patients With Moderate to Severe Crohn's Disease

Crohn Disease

Israel, United States, Romania, Ukraine, South Africa, Canada, Australia, Bulgaria, Russian Federation, New Zealand, Brazil
Genzyme, a Sanofi Company

Completed

Study in Patients With Crohn's Disease Who Are Steroid Dependent, Despite Previous Unsuccessful Attempts to Reduce Steroids Due to Worsening of Crohn's Disease

Crohn Disease
Genzyme, a Sanofi Company

Terminated

Study of Sargramostim in Moderately to Severely Active Crohn's Disease

Crohn's Disease
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Vaccine Therapy and Sargramostim in Treating Patients With Non-small Cell Lung Cancer

Lung Cancer

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia

United States
University of Colorado, Denver
EDAP TMS S.A.

Completed

The Immuno-Response to Primary Cryotherapy for the Treatment of Prostate Cancer

Recurrent Prostate Cancer | Stage I Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
Marilyn Dodd
National Cancer Institute (NCI)

Completed

GM-CSF Mouthwash for Preventing and Treating Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer

Head and Neck Cancer | Radiation Toxicity | Tongue Cancer | Mucositis Oral

United States
University of Washington

Completed

HER-2/Neu Vaccine Plus GM-CSF in Treating Patients With Stage III or Stage IV Breast, Ovarian, or Non-small Cell Lung Cancer

Breast Cancer | Ovarian Cancer | Lung Cancer

United States
Columbia University
National Cancer Institute (NCI)

Terminated

Vaccine Therapy and Sargramostim in Treating Patients With Soft Tissue Sarcoma

Sarcoma

United States
Mark Hall
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Completed

GM-CSF for Immunomodulation Following Trauma (GIFT) Study (GIFT)

Critical Injury (Trauma) in Children

United States
Partner Therapeutics, Inc.

Completed

Study to Evaluate Pharmacokinetics, Pharmacodynamics, and Safety of Sargramostim Administered Subcutaneously, Intravenously, or by Inhalation

Drug Kinetics | Drug Effects on Physiology

Canada
Dana-Farber Cancer Institute
National Cancer Institute (NCI)

Completed

Vaccine Therapy and Sargramostim in Treating Patients With Sarcoma or Brain Tumor

Sarcoma | Brain and Central Nervous System Tumors | Gastrointestinal Stromal Tumor

United States

Search clinical trials for: sargramostim GZ402664

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mongolia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations